Isis Pharmaceuticals this week announced that the US Food and Drug Administration has fast tracked its antisense-based transthyretin amyloidosis drug ISIS-TTRRx for use in patients with familial amyloid polyneuropathy, the rarer form of the disease.

The drug is being developed by Isis in collaboration with GlaxoSmithKline. A phase II/III study is expected to start this month, triggering a $7.5 million milestone payment from GlaxoSmithKline, Isis said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

This week in Nature: Researchers describe the adaptation of organisms to environmental changes, and new insights into pig domestication.

A blog seeks to challenge the stereotype of scientists as frumpy, messy, clueless dressers.

While one researcher says cloning the mammoth may be decades away, if successful, it may lead to a theme park of species that would no longer be extinct.

This Week in Nucleic Acids Research: Researchers describe a new method to find large-scale structural variants in cancer genomes, a glimpse at an approach for profiling miRNAs in tumor samples from TCGA, and more.

Sep
10
Sponsored by
Qiagen

In this online seminar, Jo Vandesompele of the Center for Medical Genetics at Ghent University will discuss methods for improving the analysis of microRNA expression from a range of samples.